Having experienced several failures, such as production delays and rare cases of serious side effects, AstraZeneca now has good news. There appears to be no additional risk of blood clots after the second dose.
The study found that the estimated rate of thrombocytopenic syndrome (TTS) after the first dose was 8,1 per million in those vaccinated.
After the second dose of the vaccine with the signal Vaxzevria, the rate was 2,3 per million, comparable to that seen in unvaccinated people, the Anglo-Swedish company added.
Tired of so many failures in the past, AstraZeneca has seen several countries restrict or stop using its vaccine, be criticized by regulators and receive warning labels.
The European Union (EU) drug regulator has been investigating TTS cases since March and has found a possible link to Vaxzevria and its single dose of Covid-19. Johnson & Johnson.
However, he argued that the overall benefits of both vaccines outweighed the risks involved.
Wednesday's findings assessed the incidents reported on April 30 and occurred within 14 days of taking the first or second dose, using AstraZeneca's global safety database.
The study said the limitations of the analysis included reliance on data provided by healthcare providers and those who had been vaccinated, which could lead to an underestimation of the incidence.
He added that "increased media attention may have led to an incorrect classification of events".
Thirteen cases of TTS were detected worldwide after the second dose in people aged 45 to 85 years, including eight women.
Some 399 cases were reported after the first dose, according to the study, while data used on the number of doses administered were limited to the EU, the European Economic Area and the United Kingdom.
The EU drug regulator in May advised not to give a second dose of the AstraZeneca vaccine to people who reported TTS after the first.